Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2005
09/09/2005WO2004082463A3 Folate receptor gene modulation for cancer diagnosis and therapy
09/09/2005WO2004080482A8 Use of angiotensin converting enzyme (ace) inhibitors to prevent diabetes in a subject with chronic heart failure
09/09/2005WO2004080371A3 Injectable isotonic solution of gatifloxacin pre-diluted in glucose.
09/09/2005WO2004078925A3 Methods and compositions for treating and preventing neurodegenerative diseases
09/09/2005WO2004075824A8 Pharmaceutical compositions for nasal delivery
09/09/2005WO2004064777A3 Modified polysaccharides combination with anti-cancer drugs for enhanced treatment of cancer
09/09/2005WO2004064762A3 Novel cocrystallization
09/09/2005WO2004064542A8 Composition for oral administration containing capsaicinoids
09/09/2005CA2846382A1 Iron based compounds for elastogenesis and connective tissue treatment
09/09/2005CA2691611A1 Myocardial perfusion imaging using adenosine receptor agonists
09/09/2005CA2599304A1 Cell targeting conjugates
09/09/2005CA2599022A1 Opioid delivery system
09/09/2005CA2562871A1 Iron based compounds for elastogenesis and connective tissue treatment
09/09/2005CA2560664A1 Benzothiazin-3-one compound and intermediate therefor
09/09/2005CA2558106A1 Inhibitors of dipeptidylpeptidase iv for regulating glucose metabolism
09/09/2005CA2557809A1 Treatment of interstitial cystitis with vitamin d compounds
09/09/2005CA2557547A1 Isoquinoline derivatives and methods of use thereof
09/09/2005CA2557541A1 Pyrimidine derivatives
09/09/2005CA2557504A1 Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor
09/09/2005CA2557499A1 Il-13 mutein proteins, antibodies, compositions, methods and uses
09/09/2005CA2557489A1 Piperidine derivatives
09/09/2005CA2557471A1 Methods and compositions for the intravenous administration of compounds related to proton pump inhibitors
09/09/2005CA2557444A1 Furosemide derivatives as modulators of hm74 and their use for the treatment of inflammation
09/09/2005CA2557411A1 Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants
09/09/2005CA2557398A1 Benzimidazolyl derivatives as kinase inhibitors
09/09/2005CA2557359A1 Semicarbazide derivatives as kinase inhibitors
09/09/2005CA2557326A1 Combination of ad-p53 and chemotherapy for the treatment of tumours
09/09/2005CA2557323A1 Alginate viscoelastic composition, method of use and package
09/09/2005CA2557278A1 Glucocorticoid receptor modulator compounds and methods- utility
09/09/2005CA2557276A1 Preventive and/or therapeutic agent for neutrophilic inflammatory diseases
09/09/2005CA2557216A1 Heparin for the treatment of ocular pathologies
09/09/2005CA2557215A1 Tetracycline derivatives for the treatment of ocular pathologies
09/09/2005CA2557162A1 Coumarin derivative and use thereof
09/09/2005CA2557144A1 Non-peptidyl agents with phsp20-like activity, and uses thereof
09/09/2005CA2557142A1 Method for providing antimicrobial composite yarns, composite fabrics and articles made therefrom
09/09/2005CA2557075A1 Methylation inhibitor compounds
09/09/2005CA2556931A1 Use of 2-methylene-19-nor-20(s)-1.alpha.,25-dihydroxyvitamin d3 for the prophylaxis of bone diseases
09/09/2005CA2556914A1 Amines and amides for the treatment of diseases
09/09/2005CA2556889A1 Dibenzo chromene derivatives and their use as er.beta. selective ligands
09/09/2005CA2556872A1 Modulation of inflammatory and metastatic processes
09/09/2005CA2556830A1 Methods and compositions comprising non-peptide small molecules that solubilize beta amyloid peptide fiber
09/09/2005CA2556823A1 Use of beta-lapachone for the treatment of lung cancer
09/09/2005CA2556794A1 Use of beta-lapachone as a broad spectrum anti-cancer agent
09/09/2005CA2556789A1 Use of beta-lapachone for treating hematologic tumors
09/09/2005CA2556768A1 Piperidinyl targeting compounds that selectively bind integrins
09/09/2005CA2556759A1 Beta-lapachone and s-phase drug combinations for cancer treatment
09/09/2005CA2556758A1 Use of beta-lapachone for treating or preventing cancer
09/09/2005CA2556756A1 Compositions comprising prodrugs of proton pump inhibitors
09/09/2005CA2556753A1 Compositions and methods for sleep regulation
09/09/2005CA2556752A1 Heterocyclic self-immolative linkers and conjugates
09/09/2005CA2556738A1 Tetracyclic lactam derivatives and uses thereof
09/09/2005CA2556729A1 Muc1 antagonist enhancement of death receptor ligand-induced apoptosis
09/09/2005CA2556616A1 Compounds as inhibitors of cell proliferation and viral infections
09/09/2005CA2556437A1 Use of targeted oxidative therapeutic formulation in treatment of viral diseases
09/09/2005CA2556114A1 Method for the production of hyperbranched polysaccharide fractions
09/09/2005CA2556064A1 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof, and the use of the same as medicaments
09/09/2005CA2556053A1 Administration of enoxaparin sodium to patients with severe renal impairment
09/09/2005CA2556025A1 Method of treating abnormal cell growth using c-met and m-tor inhibitors
09/09/2005CA2555950A1 Use of beta-lapachone for the treatment of pancreatic cancer
09/09/2005CA2555941A1 Use of beta-lapachone for treatment of colon cancer
09/09/2005CA2555724A1 2-(pyridin-3-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
09/09/2005CA2555720A1 Isoquinoline derivatives
09/09/2005CA2555711A1 Maleiimide anti-tumor phosphatase inhibitors
09/09/2005CA2555552A1 Nitric oxide-releasing molecules
09/09/2005CA2555245A1 Antisense oligonucleotide modulation of stat3 expression
09/09/2005CA2555173A1 Compositions comprising hiv protease inhibitor and cytochrome p450 enzyme activity inhibitor
09/09/2005CA2555172A1 Combinations of an atypical antipsychotic and an aminomethylpyridyloxymethyl/benzisoxazole azabicyclic derivatives for treating cns disorders
09/09/2005CA2555171A1 Therapeutic combinations
09/09/2005CA2554919A1 Use of methylene amide derivatives in cardiovascular disorders
09/09/2005CA2554908A1 Pharmaceutical compositions of neurokinin receptor antagonists and cyclodextrin and methods for improved injection site toleration
09/09/2005CA2554823A1 Nk-1 receptor antagonists to improve anesthesia recovery
09/09/2005CA2554627A1 Immunosuppressant compounds and compositions
09/09/2005CA2554486A1 Treatment of bacterial infections
09/09/2005CA2554439A1 Hydrazide type compounds and the use thereof in pharmaceutical compositions for the treatment of cardiovascular diseases
09/09/2005CA2554436A1 Use of 14,15-dihydro-20,21-dinoreburnamenin-14-ol for the treatment and/or prevention of serious depression and sleep/waking cycle disorders
09/09/2005CA2554435A1 Oral dieting composition comprising conjugated linoleic acid and caffeine
09/09/2005CA2553895A1 Use of substituted 1,2,3 indolizine derivatives for treatingdiseases associated with a pathological choroidal angiogenesis
09/09/2005CA2553725A1 Topical compositions combining sodium hyaluronate fragments and a retinoid
09/09/2005CA2553291A1 Combination of .gamma.-aminobutyric acid modulators and 5-ht1b receptor antagonists
09/09/2005CA2548770A1 A medical solution, a method for producing said medical solution and use thereof
09/09/2005CA2546853A1 Use of interfering rna in the production of transgenic animals
09/09/2005CA2543861A1 Novel pyridine derivative and pyrimidine derivative (2)
09/09/2005CA2543859A1 Novel pyridine derivative and pyrimidine derivative (1)
09/08/2005US20050198694 Truncated fragments of alpha-synuclein in Lewy body disease
09/08/2005US20050197637 Trans-scleral drug delivery method and apparatus
09/08/2005US20050197511 Reacting an acid and an amine; apoptosis; carbamate, and N-phenethyl-2-phenylacetamide
09/08/2005US20050197497 Used to improve the therapeutic efficacy of current cancer treatment; sensitizing cancerous cells to treatment with conventional anti-tumor drugs
09/08/2005US20050197421 Process for preparation of cyanoacrylate compositions
09/08/2005US20050197408 Perfluoropolyether derivative
09/08/2005US20050197407 applying a topical preparation comprising idebenone or derivative of idebenone, for treatment of skin disorders
09/08/2005US20050197406 Method of treatment of lung cancer
09/08/2005US20050197405 Treatment of hematologic tumors and cancers with beta-lapachone, a broad spectrum anti-cancer agent
09/08/2005US20050197404 Polymorphic forms of sertraline hydrochloride
09/08/2005US20050197403 2-Methylamino-N-{2-(6-{1-methyl-2-(2-methylamino-propionylamino)-3-oxo-3-[2-(5-phenoxy-tetrazol-1-ylmethyl)-pyrrolidine-1-yl]-propoxy}-hexa-2,4-diynyloxy)-1-[2-(5-phenoxy-tetrazol-1-ylmethyl)-pyrrolidine-1-carbonyl]-propyl}-propionamide; mimetics of second mitochondria-derived activator of caspases
09/08/2005US20050197402 dual mineral salt; thermal stability, simplified process
09/08/2005US20050197401 Growth factor-binding compounds and methods of use
09/08/2005US20050197400 D-penicillamine, amino guanidine, or 3 methyl-3 ethyl cysteine(MEC); to induce or to accelerate death of said abnormal cell; abnormal cell is a melanoma, a squamous carcinoma cell, an adenocarcinoma cell, an epithelial carcinoma cell, or a premalignant keratinocyte
09/08/2005US20050197399 Method of augmenting the antitumor activity of anticancer agents
09/08/2005US20050197398 mixture of isoleucine, leucine, valine, and alanine, used for treating liver disorders such as hepatitis, cirrhosis or liver cancer
09/08/2005US20050197397 Method and composition for treating mammalian diseases and injuries caused by the over-expression of peroxynitrite
1 ... 4549 4550 4551 4552 4553 4554 4555 4556 4557 4558 4559 4560 4561 4562 4563 4564 4565 4566 4567 4568 4569 ... 7860